{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:28:21Z","timestamp":1793968101568,"version":"4.8.0"},"reference-count":320,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22367016"],"award-info":[{"award-number":["22367016"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.ejmech.2026.119385","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:13:01Z","timestamp":1790723581000},"page":"119385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Multifunctional platinum(IV) prodrugs: Targeted delivery, stimuli-responsive release, and precision oncology"],"prefix":"10.1016","volume":"321","author":[{"given":"Yuming","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengmin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7390-6319","authenticated-orcid":false,"given":"Chuanzhu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119385_bib1","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00280-016-2976-z","article-title":"Platinum-based drugs: past, present and future","volume":"77","author":"Dilruba","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119385_bib2","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1021\/ed083p728","article-title":"The discovery and development of cisplatin","volume":"83","author":"Alderden","year":"2006","journal-title":"J. Chem. Educ."},{"key":"10.1016\/j.ejmech.2026.119385_bib3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1351\/pac198759020181","article-title":"The mechanism of action of platinum antitumor drugs","volume":"59","author":"Reedijk","year":"1987","journal-title":"Pure Appl. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF02307573","article-title":"Cisplatin: synthesis, antitumour activity and mechanism of action","volume":"7","author":"Reedijk","year":"1985","journal-title":"Pharm. Weekbl. - Sci. Ed."},{"key":"10.1016\/j.ejmech.2026.119385_bib5","first-page":"843","article-title":"Carboplatin: a new cisplatin analog","volume":"22","author":"Woloschuk","year":"1988","journal-title":"Drug Intell. Clin. Pharm."},{"key":"10.1016\/j.ejmech.2026.119385_bib6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ctrv.2007.01.009","article-title":"Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review","volume":"33","author":"Stordal","year":"2007","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2026.119385_bib7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1517\/14656566.2012.643870","article-title":"Oxaliplatin: a review of approved uses","volume":"13","author":"Stein","year":"2012","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2026.119385_bib8","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1023\/A:1008213732429","article-title":"Oxaliplatin: a review of preclinical and clinical studies","volume":"9","author":"Raymond","year":"1998","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2026.119385_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1634\/theoncologist.9-1-8","article-title":"FDA drug approval summaries: Oxaliplatin","volume":"9","author":"Ibrahim","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.ejmech.2026.119385_bib10","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1517\/14740338.2.6.597","article-title":"Toxicities of the platinum antineoplastic agents","volume":"2","author":"Markman","year":"2003","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.ejmech.2026.119385_bib11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0010-8545(01)00315-0","article-title":"Current status of trans-platinum compounds in cancer therapy","volume":"216\u2013217","author":"Natile","year":"2001","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.ejmech.2026.119385_bib90","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/BF00685793","article-title":"A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration","volume":"36","author":"McKeage","year":"1995","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119385_bib91","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1023\/A:1008245709924","article-title":"Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation","volume":"8","author":"Judson","year":"1997","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2026.119385_bib92","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000084201","article-title":"Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer","volume":"68","author":"Sternberg","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.ejmech.2026.119385_bib93","first-page":"98","article-title":"Phase II study of iproplatin in advanced ovarian carcinoma","volume":"6","author":"Sessa","year":"1988","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.ejmech.2026.119385_bib94","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/BF00685695","article-title":"Phase II trial of carboplatin or iproplatin in cervical cancer","volume":"28","author":"Lira-Puerto","year":"1991","journal-title":"Cancer Chemother. Pharmacol"},{"key":"10.1016\/j.ejmech.2026.119385_bib63","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3390\/nano15171320","article-title":"Hybrid Platinum(IV)-Naproxen nanostructured drugs reprogram melanoma cells and overpower cisplatin","volume":"15","author":"Komazec","year":"2025","journal-title":"Nanomaterials"},{"key":"10.1016\/j.ejmech.2026.119385_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2025.113165","article-title":"Potent anticancer 5-fluorouracil platinum(IV) prodrugs","volume":"276","author":"Khoury","year":"2026","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2026.119385_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2024.112766","article-title":"Cetirizine platinum(IV) complexes with antihistamine properties inhibit tumor metastasis by suppressing angiogenesis and boosting immunity","volume":"262","author":"Chen","year":"2025","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2026.119385_bib74","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202505930","article-title":"Evoking simultaneous ferroptosis and apoptosis by a dual\u2010locked platinum (IV) prodrug for synergistic chemo\u2010immunotherapy","volume":"64","author":"Meng","year":"2025","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119385_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101252","article-title":"A novel platinum(IV) prodrug, gramine-Pt(IV) enhances chemoimmunotherapy by activating cGAS-STING and modulating TGF-\u03b2-MHC-I axis","volume":"81","author":"Ding","year":"2025","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.ejmech.2026.119385_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2025.112910","article-title":"Repaglinide platinum(IV) conjugates: enhancing p53 signaling for antitumor and antimetastatic efficacy","volume":"268","author":"Li","year":"2025","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2026.119385_bib12","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/0024-3205(83)90299-0","article-title":"The nephrotoxicity of cisplatin","volume":"32","author":"Goldstein","year":"1983","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2026.119385_bib13","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archneur.1982.00510230045013","article-title":"Neurotoxic effects of cisplatin therapy","volume":"39","author":"Walsh","year":"1982","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ejmech.2026.119385_bib14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF00151227","article-title":"Cisplatin-induced gastric paresis","volume":"5","author":"Cohen","year":"1987","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.ejmech.2026.119385_bib15","first-page":"795","article-title":"Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity","volume":"10","author":"Gregg","year":"1992","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.ejmech.2026.119385_bib16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0093-7754(03)00399-3","article-title":"Oxaliplatin-safety profile: neurotoxicity","volume":"30","author":"Grothey","year":"2003","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119385_bib17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.tips.2005.01.002","article-title":"Mechanisms of platinum drug resistance","volume":"26","author":"Ohmichi","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2026.119385_bib18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF00254240","article-title":"Resistance ot cisplatin and analogues: mechanisms and potential clinical implications","volume":"22","author":"De Graeff","year":"1988","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119385_bib19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/path.1706","article-title":"Molecular mechanisms of drug resistance","volume":"205","author":"Longley","year":"2005","journal-title":"J. Pathol."},{"key":"10.1016\/j.ejmech.2026.119385_bib20","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Galluzzi","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.119385_bib21","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3390\/biom12101365","article-title":"Cisplatin resistance: genetic and epigenetic factors involved","volume":"12","author":"Lugones","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2026.119385_bib22","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1021\/jm070280u","article-title":"Basis for design and development of Platinum(IV) anticancer complexes","volume":"50","author":"Hall","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib23","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-07-2176","article-title":"Current status and future prospects for satraplatin, an oral platinum analogue","volume":"14","author":"Choy","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119385_bib24","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1021\/acs.chemrev.5b00597","article-title":"The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs","volume":"116","author":"Johnstone","year":"2016","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2026.119385_bib25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41578-020-00269-6","article-title":"Targeted drug delivery strategies for precision medicines","volume":"6","author":"Manzari","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.ejmech.2026.119385_bib26","doi-asserted-by":"crossref","first-page":"9907","DOI":"10.1039\/D5NR00218D","article-title":"A biotin guided PtIV amphiphilic prodrug synergized with CDK4\/6 inhibition for enhanced tumor targeted therapy","volume":"17","author":"Zhu","year":"2025","journal-title":"Nanoscale"},{"key":"10.1016\/j.ejmech.2026.119385_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202100938","article-title":"Near\u2010infrared light\u2010triggered Polyprodrug\/siRNA loaded upconversion nanoparticles for multi\u2010modality imaging and synergistic cancer therapy","volume":"10","author":"Kuang","year":"2021","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.ejmech.2026.119385_bib28","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.jconrel.2025.01.050","article-title":"Self-assembled HO-1i-Pt(IV) nanomedicine targeting p38\/MAPK and MDR pathways for cancer chemo-immunotherapy","volume":"379","author":"Liu","year":"2025","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejmech.2026.119385_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/8276139","article-title":"Current developments in Pt(IV) prodrugs conjugated with bioactive ligands","volume":"2018","author":"Li","year":"2018","journal-title":"Bioinorgan. Chem. Appl."},{"key":"10.1016\/j.ejmech.2026.119385_bib30","doi-asserted-by":"crossref","first-page":"12983","DOI":"10.1039\/C6DT01414C","article-title":"Platinum(iv) anticancer prodrugs \u2013 hypotheses and facts","volume":"45","author":"Gibson","year":"2016","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2026.119385_bib31","doi-asserted-by":"crossref","first-page":"9813","DOI":"10.1039\/c4dt00911h","article-title":"Pros and cons of bifunctional platinum(iv) antitumor prodrugs: two are (not always) better than one","volume":"43","author":"Gabano","year":"2014","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2026.119385_bib32","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1039\/D1DT03886A","article-title":"Pt(iv) antitumor prodrugs: dogmas, paradigms, and realities","volume":"51","author":"Ravera","year":"2022","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2026.119385_bib33","doi-asserted-by":"crossref","first-page":"15586","DOI":"10.1039\/D3CP01150J","article-title":"The current status in computational exploration of Pt(iv) prodrug activation by reduction","volume":"25","author":"Ponte","year":"2023","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.ejmech.2026.119385_bib34","first-page":"5660","article-title":"Investigations of the kinetics and mechanism of reduction of a carboplatin Pt(IV) prodrug by the major small-molecule reductants in human plasma","volume":"20","author":"Liu","year":"2019","journal-title":"Indian J. Manag. Sci."},{"key":"10.1016\/j.ejmech.2026.119385_bib35","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s12276-024-01180-8","article-title":"Hypoxia, oxidative stress, and the interplay of HIFs and NRF2 signaling in cancer","volume":"56","author":"Bae","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejmech.2026.119385_bib36","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1021\/acs.inorgchem.8b03486","article-title":"Antitumor Platinium(IV) prodrugs: a systematic computational exploration of their reduction mechanism by l -Ascorbic acid","volume":"58","author":"Dabbish","year":"2019","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib37","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1039\/D4QI00459K","article-title":"Advances in technical strategies for monitoring the reduction of platinum(iv) complexes","volume":"11","author":"Chen","year":"2024","journal-title":"Inorg. Chem. Front."},{"key":"10.1016\/j.ejmech.2026.119385_bib38","article-title":"Anticancer activity, reduction mechanism and G-Quadruplex DNA binding of a redox-activated Platinum(IV)\u2013Salphen complex","volume":"23","author":"Vigna","year":"2022","journal-title":"Indian J. Manag. Sci."},{"key":"10.1016\/j.ejmech.2026.119385_bib39","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1021\/acs.jmedchem.3c02393","article-title":"Promising anticancer prodrugs based on Pt(IV) complexes with bis-organosilane ligands in axial positions","volume":"67","author":"Navas","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib40","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1021\/acs.jcim.4c00315","article-title":"Machine learning-based prediction of reduction potentials for PtIV complexes","volume":"64","author":"Vigna","year":"2024","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.119385_bib41","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1002\/chem.201405467","article-title":"On the stability of PtIV pro\u2010drugs with haloacetato ligands in the axial positions","volume":"21","author":"Wexselblatt","year":"2015","journal-title":"Chem. Eur J."},{"key":"10.1016\/j.ejmech.2026.119385_bib42","doi-asserted-by":"crossref","first-page":"6059","DOI":"10.1002\/anie.201300640","article-title":"Platinum(IV) prodrugs with Haloacetato ligands in the axial positions can undergo hydrolysis under biologically relevant conditions","volume":"52","author":"Wexselblatt","year":"2013","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119385_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/cplu.202400754","article-title":"Protonation of Pt(IV) anticancer complexes assayed by vibrational ion spectroscopy","volume":"90","author":"Corinti","year":"2025","journal-title":"ChemPlusChem"},{"key":"10.1016\/j.ejmech.2026.119385_bib44","doi-asserted-by":"crossref","first-page":"8790","DOI":"10.1021\/ja5038269","article-title":"Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery","volume":"136","author":"Zheng","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.119385_bib45","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1039\/C5SC04205D","article-title":"Pt(iv) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action","volume":"7","author":"Raveendran","year":"2016","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2026.119385_bib46","doi-asserted-by":"crossref","first-page":"12132","DOI":"10.1021\/acs.jmedchem.1c00770","article-title":"Structure\u2013activity relationships of triple-action Platinum(IV) prodrugs with albumin-binding properties and immunomodulating ligands","volume":"64","author":"Fronik","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib47","doi-asserted-by":"crossref","first-page":"9440","DOI":"10.1039\/C7DT01529A","article-title":"Primary photochemical processes for Pt(iv) diazido complexes prospective in photodynamic therapy of tumors","volume":"46","author":"Shushakov","year":"2017","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2026.119385_bib48","article-title":"Recent advances in light-controlled activation of Pt(IV) prodrugs","volume":"23","author":"Spector","year":"2022","journal-title":"Indian J. Manag. Sci."},{"key":"10.1016\/j.ejmech.2026.119385_bib49","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1021\/acs.inorgchem.8b00177","article-title":"Insight into the electrochemical reduction mechanism of Pt(IV) anticancer complexes","volume":"57","author":"Tolbatov","year":"2018","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib50","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1021\/acs.chemrestox.6b00380","article-title":"DNA adducts from anticancer drugs as candidate predictive markers for precision medicine","volume":"30","author":"Stornetta","year":"2017","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2026.119385_bib51","first-page":"7392","article-title":"Interactions with DNA models of the oxaliplatin analog (cis-1,3-DACH)PtCl2","volume":"25","author":"Barbanente","year":"2024","journal-title":"Indian J. Manag. Sci."},{"key":"10.1016\/j.ejmech.2026.119385_bib52","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1042\/BCJ20180848","article-title":"Structural basis for the bypass of the major oxaliplatin\u2013DNA adducts by human DNA polymerase \u03b7","volume":"476","author":"Ouzon-Shubeita","year":"2019","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2026.119385_bib53","doi-asserted-by":"crossref","first-page":"zcad057","DOI":"10.1093\/narcan\/zcad057","article-title":"Detection of oxaliplatin- and cisplatin-DNA lesions requires different global genome repair mechanisms that affect their clinical efficacy","volume":"5","author":"Slyskova","year":"2023","journal-title":"NAR Cancer"},{"key":"10.1016\/j.ejmech.2026.119385_bib54","first-page":"7241","article-title":"Can cisplatin therapy be improved? Pathways that can be targeted","volume":"23","author":"Ali","year":"2022","journal-title":"Indian J. Manag. Sci."},{"key":"10.1016\/j.ejmech.2026.119385_bib55","article-title":"The multifaceted influence of histone deacetylases on DNA damage signalling and DNA repair","volume":"44","author":"Roos","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2026.119385_bib56","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1039\/C4SC03650F","article-title":"HMGB1 bound to cisplatin\u2013DNA adducts undergoes extensive acetylation and phosphorylation in vivo","volume":"6","author":"He","year":"2015","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2026.119385_bib57","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1158\/0008-5472.CAN-19-3066","article-title":"Targeting chromosomal architectural HMGB proteins could be the next frontier in cancer therapy","volume":"80","author":"Mukherjee","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119385_bib58","first-page":"3817","article-title":"Pt(IV) prodrugs with NSAIDs as axial ligands","volume":"22","author":"Spector","year":"2021","journal-title":"Indian J. Manag. Sci."},{"key":"10.1016\/j.ejmech.2026.119385_bib59","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00280-010-1428-4","article-title":"Satraplatin (JM-216) mediates G2\/M cell cycle arrest and potentiates apoptosis via multiple death pathways in colorectal cancer cells thus overcoming platinum chemo-resistance","volume":"67","author":"Kalimutho","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119385_bib60","first-page":"3074","article-title":"Antiproliferative activity of Pt(IV) conjugates containing the non-steroidal anti-inflammatory drugs (NSAIDs) ketoprofen and naproxen \u2020","volume":"20","author":"Ravera","year":"2019","journal-title":"Indian J. Manag. Sci."},{"key":"10.1016\/j.ejmech.2026.119385_bib61","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3390\/pharmaceutics16020278","article-title":"Oxaliplatin(IV) prodrugs functionalized with gemcitabine and capecitabine induce blockage of colorectal cancer cell growth\u2014an investigation of the activation mechanism and their nanoformulation","volume":"16","author":"Marotta","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119385_bib62","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1021\/acsomega.9b03381","article-title":"Oxaliplatin-based Platinum(IV) prodrug bearing toll-like receptor 7 agonist for enhanced immunochemotherapy","volume":"5","author":"Tang","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2026.119385_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.matchemphys.2026.132192","article-title":"Green synthesis and characterization of platinum nanoparticles loaded with paclitaxel and coated with chitosan: a promising approach for breast cancer treatment","volume":"354","author":"Al-darwesh","year":"2026","journal-title":"Mater. Chem. Phys."},{"key":"10.1016\/j.ejmech.2026.119385_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117338","article-title":"Design, synthesis and evaluation of diarylidenyl piperidone-ligated platinum (IV) complexes as chemoimmunotherapeutic agents","volume":"287","author":"Mao","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib67","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.actbio.2023.02.012","article-title":"NIR-II light evokes DNA cross-linking for chemotherapy and immunogenic cell death","volume":"160","author":"Huang","year":"2023","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ejmech.2026.119385_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106556","article-title":"Induction of immunogenic cell death by novel platinum-based anticancer agents","volume":"187","author":"Chang","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2026.119385_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117014","article-title":"More than just DNA damage: pt(\u03b9\u03b9)-nhc complexes derived from 4,5-diarylimidazoles augment immunogenic cell death","volume":"282","author":"Tang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/anie.4247438","article-title":"Au(III) complexes as pyroptosis inducers by targeting mitochondrial DNA for tumor immunity","volume":"65","author":"Lv","year":"2026","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119385_bib71","doi-asserted-by":"crossref","first-page":"10811","DOI":"10.1021\/acs.jmedchem.6c00026","article-title":"Novel dual-pharmacophore TrxR inhibitors integrating ferroptosis and antitumor immunity: a closed-loop strategy for TIME remodeling","volume":"69","author":"Xu","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib72","article-title":"Glabridin-Gold(I) complex as a novel immunomodulatory agent targeting TrxR and MAPK pathways for synergistic enhancement of antitumor immunity","volume":"12","author":"Wang","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.ejmech.2026.119385_bib77","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202501903","article-title":"NIR\u2010II D\u2013A\u2013D\u2010Type small\u2010molecule coordination with Carboxylatopillar[5]Arene: a multifunctional phototheranostic for low\u2010temperature NIR\u2010II photothermal\/platinum\u2010based\/chemodynamic combination cancer immunotherapy","volume":"21","author":"Ding","year":"2025","journal-title":"Small"},{"key":"10.1016\/j.ejmech.2026.119385_bib78","article-title":"Biotinylated platinum(IV)-conjugated graphene oxide nanoparticles for targeted chemo-photothermal combination therapy in breast cancer","volume":"168","author":"Itoo","year":"2025","journal-title":"Biomater. Adv."},{"key":"10.1016\/j.ejmech.2026.119385_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.coco.2025.102446","article-title":"Multifunctional platinum(IV) nanomicelle composites for chemo-photodynamic therapy and anti-metastasis in cancer treatment","volume":"57","author":"Wang","year":"2025","journal-title":"Compos. Commun."},{"key":"10.1016\/j.ejmech.2026.119385_bib80","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/09553002.2026.2631008","article-title":"Novel platinum(IV) complexes as potential chemotherapeutic and radiosensitizing agents in HR+ breast cancer treatment","volume":"102","author":"Popovic","year":"2026","journal-title":"Int. J. Radiat. Biol."},{"key":"10.1016\/j.ejmech.2026.119385_bib81","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3390\/ph15040480","article-title":"A Theranostic nanocomplex combining with magnetic hyperthermia for enhanced accumulation and efficacy of pH-Triggering polymeric Cisplatin(IV) prodrugs","volume":"15","author":"Qu","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.119385_bib82","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202301074","article-title":"Reduction of Platinum(IV) prodrug hemoglobin nanoparticles with deeply penetrating ultrasound radiation for tumor\u2010targeted therapeutically enhanced anticancer therapy","volume":"62","author":"Liang","year":"2023","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119385_bib83","article-title":"An ultrasound-activatable platinum prodrug for sono-sensitized chemotherapy","volume":"9","author":"Liu","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2026.119385_bib84","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1039\/D4TB02615B","article-title":"Pt(iv) prodrug as a potent nanosonosensitizer self-cyclically amplifies sonodynamic-chemotherapy with dually reversing cisplatin resistance","volume":"13","author":"Li","year":"2025","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.ejmech.2026.119385_bib85","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1039\/D5RA03591K","article-title":"Nanobiotechnology-driven advances in sonodynamic therapy: unlocking the potential of sonosensitizers in clinical translation","volume":"16","author":"Zeng","year":"2026","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2026.119385_bib86","article-title":"Ultrasound\u2010triggered Cascade delivery via poly\u2010oxaliplatin nanoparticles for immunotherapy","volume":"35","author":"Shen","year":"2025","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.ejmech.2026.119385_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2024.216169","article-title":"Current roles of metals in arming sonodynamic cancer therapy","volume":"521","author":"Chen","year":"2024","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.ejmech.2026.119385_bib88","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1038\/s41598-025-32555-0","article-title":"A dual-functional cobalt ferrite nanocomplex for targeted cisplatin prodrug delivery and MALAT1 gene silencing in gastric cancer cells","volume":"16","author":"Doryani","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119385_bib89","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3390\/cancers18040599","article-title":"Targeting STAT3 promotes tumor cell death and enhances T-Cell activity in HPV16-Positive cancer","volume":"18","author":"Prins","year":"2026","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.119385_bib95","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3390\/ph18020210","article-title":"Current trends in clinical trials of prodrugs","volume":"18","author":"Boreski","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.119385_bib96","doi-asserted-by":"crossref","DOI":"10.1002\/cnma.202300295","article-title":"Chemical and photophysical triggers for the reduction of Pt(IV) prodrugs for anticancer therapy","volume":"9","author":"Karges","year":"2023","journal-title":"ChemNanoMat"},{"key":"10.1016\/j.ejmech.2026.119385_bib97","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1517\/17425255.2012.636352","article-title":"Clinical and pharmacokinetic evaluation of satraplatin","volume":"8","author":"Doshi","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejmech.2026.119385_bib98","article-title":"A polyplatin with hands\u2010holding Near\u2010Infrared\u2010II fluorophores and prodrugs at a precise ratio for tracking drug fate with realtime readout and treatment feedback","volume":"36","author":"Yu","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ejmech.2026.119385_bib99","first-page":"1046","article-title":"Folate receptor alpha\u2014A novel approach to cancer therapy","volume":"25","author":"Gonzalez","year":"2024","journal-title":"Indian J. Manag. Sci."},{"key":"10.1016\/j.ejmech.2026.119385_bib100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1254532","article-title":"Therapeutic strategies targeting folate receptor \u03b1 for ovarian cancer","volume":"14","author":"Mai","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.119385_bib101","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2470309","article-title":"Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age","volume":"17","author":"Liu","year":"2025","journal-title":"mAbs"},{"key":"10.1016\/j.ejmech.2026.119385_bib102","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.2147\/CMAR.S549662","article-title":"Folic acid, folate conjugates and folate receptors: novel applications in imaging of cancer and inflammation-related conditions","volume":"17","author":"Chegeni","year":"2025","journal-title":"CMAR"},{"key":"10.1016\/j.ejmech.2026.119385_bib103","article-title":"A novel folate receptor-targeted curcumin nano-delivery system: a dual therapeutic strategy for precise inhibition of MRCK\u03b2 to suppress ovarian cancer proliferation and immune escape","volume":"35","author":"Shi","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.ejmech.2026.119385_bib104","first-page":"2152","article-title":"Enhancement of binding affinity of folate to its receptor by peptide conjugation","volume":"20","author":"Dharmatti","year":"2019","journal-title":"Indian J. Manag. Sci."},{"key":"10.1016\/j.ejmech.2026.119385_bib105","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s11095-009-9840-3","article-title":"Properties influencing the relative binding affinity of pteroate derivatives and drug conjugates thereof to the folate receptor","volume":"26","author":"Leamon","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejmech.2026.119385_bib106","doi-asserted-by":"crossref","first-page":"11467","DOI":"10.1021\/ja803036e","article-title":"Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device","volume":"130","author":"Dhar","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.119385_bib107","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.3390\/biomedicines11072080","article-title":"Evaluation of folate-functionalized nanoparticle drug delivery systems\u2014Effectiveness and concerns","volume":"11","author":"Ibrahim","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2026.119385_bib108","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/cplu.201402342","article-title":"Folate\u2013cyclodextrin conjugates as carriers of the Platinum(IV) complex LA\u201012","volume":"80","author":"Giglio","year":"2015","journal-title":"ChemPlusChem"},{"key":"10.1016\/j.ejmech.2026.119385_bib109","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70392","article-title":"The efficacy and safety of folate receptor \u03b1\u2010Targeted antibody\u2010drug conjugate therapy in patients with high\u2010grade epithelial ovarian, primary peritoneal, or fallopian tube cancers: a systematic review and meta\u2010analysis","volume":"13","author":"Kim","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.ejmech.2026.119385_bib110","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/ajhp\/zxaf011","article-title":"A review of mirvetuximab soravtansine-gynx in folate receptor alpha\u2013expressing platinum-resistant ovarian cancer","volume":"82","author":"Smith","year":"2025","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.ejmech.2026.119385_bib111","first-page":"1112","article-title":"Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha\u2013targeting antibody\u2013drug conjugate, in platinum-resistant ovarian, Fallopian tube, or primary peritoneal cancer: a phase I expansion study","volume":"35","author":"Moore","year":"2017","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.ejmech.2026.119385_bib112","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jconrel.2017.02.023","article-title":"Folate-mediated chemotherapy and diagnostics: an updated review and outlook","volume":"252","author":"Xu","year":"2017","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejmech.2026.119385_bib113","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s10555-008-9158-3","article-title":"Imaging of integrin \u03b1v\u03b23 expression","volume":"27","author":"Beer","year":"2008","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ejmech.2026.119385_bib114","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ddr.20265","article-title":"Integrin \u03b1v \u03b23 \u2010targeted cancer therapy","volume":"69","author":"Liu","year":"2008","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ejmech.2026.119385_bib115","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1126\/science.7512751","article-title":"Requirement of vascular integrin cV4I3 for angiogenesis","volume":"264","author":"Brooks","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119385_bib116","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.3390\/ph17111556","article-title":"Integrin targeting and beyond: enhancing cancer treatment with dual-targeting RGD (Arginine\u2013Glycine\u2013Aspartate) strategies","volume":"17","author":"Bogdanovi\u0107","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.119385_bib117","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.6800","article-title":"RGD peptide in cancer targeting: benefits, challenges, solutions, and possible integrin\u2013RGD interactions","volume":"13","author":"Javid","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.ejmech.2026.119385_bib118","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s42004-026-01886-y","article-title":"Identification of an \u03b1v\u03b23-targeting bicyclic peptide with atypical norArg-Gly-Asp sequence","volume":"9","author":"Yang","year":"2026","journal-title":"Commun. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib119","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1039\/C4DT02710H","article-title":"Integrin-targeted delivery into cancer cells of a Pt(iv) pro-drug through conjugation to RGD-containing peptides","volume":"44","author":"Massaguer","year":"2015","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2026.119385_bib120","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1021\/nn301148e","article-title":"\u03b1V \u03b23 integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug","volume":"6","author":"Graf","year":"2012","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejmech.2026.119385_bib121","doi-asserted-by":"crossref","first-page":"7913","DOI":"10.2147\/IJN.S146505","article-title":"\u03b1v\u03b23 integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo","volume":"12","author":"Zhong","year":"2017","journal-title":"IJN"},{"key":"10.1016\/j.ejmech.2026.119385_bib122","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1039\/D5MD00280J","article-title":"Macrocyclic RGD-peptides with high selectivity for \u03b1v \u03b23 integrin in cancer imaging and therapy","volume":"16","author":"Cheng","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib123","first-page":"3143","article-title":"Integrins in cancer drug resistance: molecular mechanisms and clinical implications","volume":"26","author":"Kariya","year":"2025","journal-title":"Indian J. Manag. Sci."},{"key":"10.1016\/j.ejmech.2026.119385_bib124","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.863850","article-title":"Targeting integrins for cancer therapy - disappointments and opportunities","volume":"10","author":"Bergonzini","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2026.119385_bib125","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s12276-025-01436-x","article-title":"Transferrin receptors","volume":"57","author":"Guo","year":"2025","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejmech.2026.119385_bib126","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.bbagen.2011.07.016","article-title":"The transferrin receptor and the targeted delivery of therapeutic agents against cancer","volume":"1820","author":"Daniels","year":"2012","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.ejmech.2026.119385_bib127","first-page":"9793","article-title":"Targeting transferrin receptor 1 for enhancing drug delivery through the blood\u2013brain barrier for Alzheimer's disease","volume":"26","author":"Shen","year":"2025","journal-title":"Indian J. Manag. Sci."},{"key":"10.1016\/j.ejmech.2026.119385_bib128","article-title":"New transferrin receptor\u2010targeting conjugate effectively delivers DNA to mouse brain","volume":"64","author":"Song","year":"2025","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119385_bib129","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3390\/pharmaceutics14102237","article-title":"Blood\u2013brain barrier transport of transferrin receptor-targeted nanoparticles","volume":"14","author":"Thomsen","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119385_bib130","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1016\/S0021-9258(19)34036-0","article-title":"Regulation of ferritin and transferrin receptor mRNAs","volume":"265","author":"Theil","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib131","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/pharmaceutics14020279","article-title":"Transferrin receptor-targeted nanocarriers: overcoming barriers to treat glioblastoma","volume":"14","author":"Ramalho","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119385_bib132","doi-asserted-by":"crossref","first-page":"8339","DOI":"10.2147\/IJN.S187240","article-title":"Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy","volume":"13","author":"Ke","year":"2018","journal-title":"IJN"},{"key":"10.1016\/j.ejmech.2026.119385_bib133","article-title":"Pathophysiological aspects of transferrin-A potential nano-based drug delivery signaling molecule in therapeutic target for varied diseases","volume":"15","author":"Li","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119385_bib134","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1039\/D4MD00652F","article-title":"Hepatocyte targeting via the asialoglycoprotein receptor","volume":"16","author":"Ram\u00edrez-Cort\u00e9s","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib135","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1080\/19420862.2017.1373924","article-title":"Capacity limits of asialoglycoprotein receptor-mediated liver targeting","volume":"9","author":"Bon","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.ejmech.2026.119385_bib136","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2025.2554896","article-title":"Biotin-mediated drug delivery: does the biotin transporter mediate uptake of biotin conjugates?","volume":"40","author":"Tripathi","year":"2025","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib137","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2023.2276663","article-title":"Biotin conjugates in targeted drug delivery: is it mediated by a biotin transporter, a yet to be identified receptor, or (an)other unknown mechanism(s)?","volume":"38","author":"Tripathi","year":"2023","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib138","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.3390\/pharmaceutics14122780","article-title":"Potent Platinum(IV) prodrugs that incorporate a biotin moiety to selectively target cancer cells","volume":"14","author":"Khoury","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119385_bib139","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1039\/D2DT03662B","article-title":"Biotinylated Pt(iv) prodrugs with elevated lipophilicity and cytotoxicity","volume":"52","author":"Spector","year":"2023","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2026.119385_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122049","article-title":"Biotin receptor-targeting nanogels loaded with methotrexate for enhanced antitumor efficacy in triple-negative breast cancer in vitro and in vivo models","volume":"624","author":"Sadat Abolmaali","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2026.119385_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117829","article-title":"PSMA targeted therapy: from molecular mechanisms to clinical breakthroughs in castration-resistant prostate cancer","volume":"296","author":"Wang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib142","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","article-title":"Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer","volume":"22","author":"Bakht","year":"2025","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.ejmech.2026.119385_bib143","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3390\/cancers13030417","article-title":"Small molecule-based prodrug targeting prostate specific membrane antigen for the treatment of prostate cancer","volume":"13","author":"Wang","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.119385_bib144","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41391-021-00394-5","article-title":"Advances in PSMA-targeted therapy for prostate cancer","volume":"25","author":"Wang","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.ejmech.2026.119385_bib145","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.847835","article-title":"Antibody-drug conjugates targeting the human epidermal growth factor receptor family in cancers","volume":"9","author":"Yu","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ejmech.2026.119385_bib146","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3390\/biology14081011","article-title":"Epidermal growth factor receptor (EGFR)-targeting peptides and their applications in tumor imaging probe construction: current advances and future perspectives","volume":"14","author":"Huang","year":"2025","journal-title":"Biology"},{"key":"10.1016\/j.ejmech.2026.119385_bib147","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.7150\/thno.14302","article-title":"HER2 targeting peptides screening and applications in tumor imaging and drug delivery","volume":"6","author":"Geng","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2026.119385_bib148","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1021\/acs.jmedchem.5c02536","article-title":"Tumor-targeted delivery of an EGFR inhibitor prodrug via site-specific albumin conjugation","volume":"69","author":"Federa","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib149","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00775-017-1450-7","article-title":"EGFR-targeting peptide-coupled platinum(IV) complexes","volume":"22","author":"Mayr","year":"2017","journal-title":"J. Biol. Inorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib150","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.2353\/ajpath.2009.080596","article-title":"GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis","volume":"174","author":"Amann","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejmech.2026.119385_bib151","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1590\/S1807-59322011000600008","article-title":"GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker","volume":"66","author":"Carvalho","year":"2011","journal-title":"Clinics"},{"key":"10.1016\/j.ejmech.2026.119385_bib152","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.bmc.2019.03.006","article-title":"Glucose-conjugated platinum(IV) complexes as tumor-targeting agents: design, synthesis and biological evaluation","volume":"27","author":"Wang","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib153","doi-asserted-by":"crossref","first-page":"5736","DOI":"10.1021\/acs.jmedchem.7b00433","article-title":"Glycosylated Platinum(IV) complexes as substrates for glucose transporters (GLUTs) and organic cation transporters (OCTs) exhibited cancer targeting and human serum albumin binding properties for drug delivery","volume":"60","author":"Ma","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib154","doi-asserted-by":"crossref","first-page":"39476","DOI":"10.18632\/oncotarget.17073","article-title":"GLUT1-mediated selective tumor targeting with fluorine containing platinum(II) glycoconjugates","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2026.119385_bib155","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3389\/fchem.2018.00386","article-title":"Protected and De-protected Platinum(IV) glycoconjugates with GLUT1 and OCT2-Mediated selective cancer targeting: demonstrated enhanced transporter-mediated cytotoxic properties in vitro and in vivo","volume":"6","author":"Ma","year":"2018","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2021.111653","article-title":"Mitochondria-targeted Pt(IV) prodrugs conjugated with an aggregation-induced emission luminogen against breast cancer cells by dual modulation of apoptosis and autophagy inhibition","volume":"226","author":"Su","year":"2022","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2026.119385_bib157","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2147\/CPAA.S526895","article-title":"Triphenylphosphine-based mitochondrial targeting nanocarriers: advancing cancer therapy","volume":"17","author":"Ali","year":"2025","journal-title":"CPAA"},{"key":"10.1016\/j.ejmech.2026.119385_bib158","doi-asserted-by":"crossref","first-page":"21156","DOI":"10.1021\/acsnano.4c04024","article-title":"Mitochondria-targeted multifunctional nanoprodrugs by inhibiting metabolic reprogramming for combating cisplatin-resistant lung cancer","volume":"18","author":"Lu","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejmech.2026.119385_bib159","doi-asserted-by":"crossref","first-page":"10043","DOI":"10.1021\/acs.chemrev.7b00042","article-title":"Mitochondria-targeted triphenylphosphonium-based compounds: syntheses, mechanisms of action, and therapeutic and diagnostic applications","volume":"117","author":"Zielonka","year":"2017","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2026.119385_bib160","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.3390\/molecules30224413","article-title":"Mitochondrial-targeted triphenylphosphonium-conjugated ionophores with enhanced cytotoxicity in cancer cells","volume":"30","author":"Sulik","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119385_bib161","first-page":"6790","article-title":"Triphenylphosphonium-conjugated palmitic acid for mitochondrial targeting of pancreatic cancer cells: proteomic and molecular evidence","volume":"25","author":"Siragusa","year":"2024","journal-title":"Indian J. Manag. Sci."},{"key":"10.1016\/j.ejmech.2026.119385_bib162","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejmech.2018.09.008","article-title":"Novel tacrine platinum(II) complexes display high anticancer activity via inhibition of telomerase activity, dysfunction of mitochondria, and activation of the p53 signaling pathway","volume":"158","author":"Qin","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib163","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ejmech.2018.06.018","article-title":"Mitochondria-targeted platinum(II) complexes induce apoptosis-dependent autophagic cell death mediated by ER-stress in A549 cancer cells","volume":"155","author":"Wang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib164","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.freeradbiomed.2018.09.040","article-title":"New Platinum(II) agent induces bimodal death of apoptosis and autophagy against A549 cancer cell","volume":"129","author":"Wang","year":"2018","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejmech.2026.119385_bib165","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1021\/acs.jmedchem.2c01924","article-title":"A clinically translatable ternary Platinum(IV) prodrug for synergistically reversing drug resistance","volume":"66","author":"Liu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib166","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3390\/plants15020183","article-title":"Biogenic approaches to metal nanoparticle synthesis and their application in biotechnology","volume":"15","author":"Yugay","year":"2026","journal-title":"Plants"},{"key":"10.1016\/j.ejmech.2026.119385_bib167","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/jccs.70169","article-title":"The transformative role of metal\u2010based nanoparticles in modern biomedicine","volume":"73","author":"Inam","year":"2026","journal-title":"J Chinese Chemical Soc"},{"key":"10.1016\/j.ejmech.2026.119385_bib168","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117493","article-title":"Advances in stimuli-responsive gold nanorods for drug-delivery and targeted therapy systems","volume":"180","author":"Hajebi","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2026.119385_bib169","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.3390\/pharmaceutics16101332","article-title":"Review of gold nanoparticles: synthesis, properties, shapes, cellular uptake, targeting, release mechanisms and applications in drug delivery and therapy","volume":"16","author":"Georgeous","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119385_bib170","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.3390\/pharmaceutics15071868","article-title":"Gold nanoparticles: construction for drug delivery and application in cancer immunotherapy","volume":"15","author":"Huang","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119385_bib171","doi-asserted-by":"crossref","first-page":"9217","DOI":"10.1039\/D5TB01007A","article-title":"Pt(iv)-functionalised polyacrylic acid-coated iron oxide magnetic nanoparticles as redox-responsive cancer theranostics","volume":"13","author":"Brito","year":"2025","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.ejmech.2026.119385_bib172","doi-asserted-by":"crossref","first-page":"6278","DOI":"10.7150\/thno.42564","article-title":"Multifunctional magnetic iron oxide nanoparticles: an advanced platform for cancer theranostics","volume":"10","author":"Zhao","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2026.119385_bib173","first-page":"227","article-title":"Multifunctional iron oxide nanoparticles as promising magnetic biomaterials in drug delivery: a review","volume":"15","author":"Vasi\u0107","year":"2024","journal-title":"J. Forensic Biomech."},{"key":"10.1016\/j.ejmech.2026.119385_bib174","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2026.111953","article-title":"Neurotoxicity and mechanism of metal and metal oxide nanoparticles","volume":"428","author":"Cao","year":"2026","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2026.119385_bib175","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/adma.201104763","article-title":"Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery","volume":"24","author":"Tang","year":"2012","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ejmech.2026.119385_bib176","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1039\/c3cs35405a","article-title":"Synthesis of mesoporous silica nanoparticles","volume":"42","author":"Wu","year":"2013","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2026.119385_bib177","doi-asserted-by":"crossref","DOI":"10.15406\/jnmr.2015.02.00043","article-title":"Mesoporous silica nanoparticles (MSN): a nanonetwork and hierarchical structure in drug delivery","volume":"2","author":"Jadhav","year":"2015","journal-title":"JNMR"},{"key":"10.1016\/j.ejmech.2026.119385_bib178","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.nano.2014.09.014","article-title":"Mesoporous silica nanoparticles in drug delivery and biomedical applications","volume":"11","author":"Wang","year":"2015","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.ejmech.2026.119385_bib179","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.3390\/pharmaceutics17121602","article-title":"Advances in mesoporous silica and hybrid nanoparticles for drug delivery: synthesis, functionalization, and biomedical applications","volume":"17","author":"Almatroudi","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119385_bib180","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/bioengineering4010003","article-title":"pH-Responsive mesoporous silica and carbon nanoparticles for drug delivery","volume":"4","author":"Gisbert-Garzar\u00e1n","year":"2017","journal-title":"Bioengineering"},{"key":"10.1016\/j.ejmech.2026.119385_bib181","first-page":"34","article-title":"pH-responsive mesoporous silica nanoparticles employed in controlled drug delivery systems for cancer treatment","volume":"11","author":"Yang","year":"2014","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.ejmech.2026.119385_bib182","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.3390\/nano11092222","article-title":"Redox-responsive mesoporous silica nanoparticles for cancer treatment: recent updates","volume":"11","author":"Gisbert-Garzar\u00e1n","year":"2021","journal-title":"Nanomaterials"},{"key":"10.1016\/j.ejmech.2026.119385_bib183","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1039\/C3BM60148J","article-title":"Stimuli-responsive functionalized mesoporous silica nanoparticles for drug release in response to various biological stimuli","volume":"2","author":"Chen","year":"2014","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.ejmech.2026.119385_bib184","doi-asserted-by":"crossref","DOI":"10.1016\/j.jallcom.2024.173624","article-title":"CuS-NPs, GQD, MSN-NPs and doxorubicin: an excellent nano-compound for cancer treatment by chemo-photodynamic therapy","volume":"980","author":"Gharibzadeh","year":"2024","journal-title":"J. Alloys Compd."},{"key":"10.1016\/j.ejmech.2026.119385_bib185","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1080\/10717544.2016.1209796","article-title":"pH responsive cylindrical MSN for oral delivery of insulin-design, fabrication and evaluation","volume":"23","author":"Guha","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejmech.2026.119385_bib186","doi-asserted-by":"crossref","first-page":"7133","DOI":"10.2147\/IJN.S436253","article-title":"A novel pH-Responsive iron oxide core-shell magnetic mesoporous silica nanoparticle (M-MSN) system encapsulating doxorubicin (DOX) and glucose oxidase (Gox) for pancreatic cancer treatment","volume":"18","author":"Qi","year":"2023","journal-title":"IJN"},{"key":"10.1016\/j.ejmech.2026.119385_bib187","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3390\/pharmaceutics13040570","article-title":"Mesoporous silica nanoparticles: properties and strategies for enhancing clinical effect","volume":"13","author":"Frickenstein","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119385_bib188","doi-asserted-by":"crossref","first-page":"23975","DOI":"10.1002\/anie.202106259","article-title":"The current status of MOF and COF applications","volume":"60","author":"Freund","year":"2021","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119385_bib189","doi-asserted-by":"crossref","first-page":"15188","DOI":"10.1002\/anie.201902229","article-title":"Mixed\u2010metal MOFs: unique opportunities in metal\u2013organic framework (MOF) functionality and design","volume":"58","author":"Masoomi","year":"2019","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119385_bib190","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1021\/acs.chemrev.9b00223","article-title":"State of the art and prospects in metal\u2013organic framework (MOF)-based and MOF-derived nanocatalysis","volume":"120","author":"Wang","year":"2020","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2026.119385_bib191","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1021\/acs.accounts.8b00521","article-title":"Metal\u2013organic frameworks for photocatalysis and photothermal catalysis","volume":"52","author":"Xiao","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejmech.2026.119385_bib192","doi-asserted-by":"crossref","first-page":"9378","DOI":"10.1039\/D4CS00095A","article-title":"Metal\u2013organic frameworks for organic transformations by photocatalysis and photothermal catalysis","volume":"53","author":"Jin","year":"2024","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2026.119385_bib193","doi-asserted-by":"crossref","first-page":"11453","DOI":"10.1021\/acs.analchem.0c02599","article-title":"Mineralization of pH-Sensitive doxorubicin prodrug in ZIF-8 to enable targeted delivery to solid tumors","volume":"92","author":"Yan","year":"2020","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib194","doi-asserted-by":"crossref","first-page":"5523","DOI":"10.2147\/IJN.S462480","article-title":"Biomimetic ZIF-8 nanoparticles: a novel approach for biomimetic drug delivery systems","volume":"19","author":"Wang","year":"2024","journal-title":"IJN"},{"key":"10.1016\/j.ejmech.2026.119385_bib195","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2025.e42685","article-title":"Cisplatin-loaded UiO-66-NH2 functionalized with folic acid enhances apoptotic activity and antiproliferative effects in MDA-MB-231 breast and A2780 ovarian cancer cells: an in vitro study","volume":"11","author":"Sadeghi Jam","year":"2025","journal-title":"Heliyon"},{"key":"10.1016\/j.ejmech.2026.119385_bib196","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3390\/pharmaceutics17040512","article-title":"Silver nanoparticles decorated UiO-66-NH2 metal-organic framework for combination therapy in cancer treatment","volume":"17","author":"Ragonese","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119385_bib197","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.126540","article-title":"An intelligent responsive ZIF-8 co-delivery nanoplatform with multimodal synergistic technologies for closed-loop therapy of tumors","volume":"690","author":"Chen","year":"2026","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2026.119385_bib198","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/IJN.S429279","article-title":"Advancing therapeutic strategies with polymeric drug conjugates for nucleic acid delivery and treatment","volume":"20","author":"Ullah","year":"2025","journal-title":"IJN"},{"key":"10.1016\/j.ejmech.2026.119385_bib199","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41573-018-0005-0","article-title":"Polymer\u2013drug conjugate therapeutics: advances, insights and prospects","volume":"18","author":"Ekladious","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119385_bib200","doi-asserted-by":"crossref","first-page":"9136","DOI":"10.1016\/j.biomaterials.2011.08.022","article-title":"Platinum (IV)-coordinate polymers as intracellular reduction-responsive backbone-type conjugates for cancer drug delivery","volume":"32","author":"Yang","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejmech.2026.119385_bib201","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/btm2.10033","article-title":"Anticancer nanoparticulate polymer\u2010drug conjugate","volume":"1","author":"Feng","year":"2016","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.119385_bib202","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/mabi.201600035","article-title":"Macromolecular Pt(IV) prodrugs from poly(organo)phosphazenes","volume":"16","author":"Henke","year":"2016","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.ejmech.2026.119385_bib203","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1039\/D2CS01060G","article-title":"Stimuli-sensitive polymer prodrug nanocarriers by reversible-deactivation radical polymerization","volume":"53","author":"Guerassimoff","year":"2024","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2026.119385_bib204","first-page":"215","article-title":"MOFs and MOF-derived materials for antibacterial application","volume":"13","author":"Zhang","year":"2022","journal-title":"J. Forensic Biomech."},{"key":"10.1016\/j.ejmech.2026.119385_bib205","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/polym14020287","article-title":"NIR and reduction dual-sensitive polymeric prodrug nanoparticles for bioimaging and combined chemo-phototherapy","volume":"14","author":"Li","year":"2022","journal-title":"Polymers"},{"key":"10.1016\/j.ejmech.2026.119385_bib206","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2023.2171158","article-title":"Novel Pt(IV) prodrug self-assembled nanoparticles with enhanced blood circulation stability and improved antitumor capacity of oxaliplatin for cancer therapy","volume":"30","author":"Fu","year":"2023","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejmech.2026.119385_bib207","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1039\/C7TB00178A","article-title":"Pt(iv) prodrug-backboned micelle and DCA loaded nanofibers for enhanced local cancer treatment","volume":"5","author":"Zhang","year":"2017","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.ejmech.2026.119385_bib208","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.actbio.2018.07.041","article-title":"Bacterial microbots for acid-labile release of hybrid micelles to promote the synergistic antitumor efficacy","volume":"78","author":"Xie","year":"2018","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ejmech.2026.119385_bib209","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1039\/C6TB03282F","article-title":"Redox\/pH dual-sensitive hybrid micelles for targeting delivery and overcoming multidrug resistance of cancer","volume":"5","author":"Yin","year":"2017","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.ejmech.2026.119385_bib210","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.802785","article-title":"Fabrication of pH\/Redox dual-responsive mixed polyprodrug micelles for improving cancer chemotherapy","volume":"12","author":"Luo","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119385_bib211","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2020.111256","article-title":"Hybrid micelles based on Pt (IV) polymeric prodrug and TPGS for the enhanced cytotoxicity in drug-resistant lung cancer cells","volume":"195","author":"He","year":"2020","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ejmech.2026.119385_bib212","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/cancers10070238","article-title":"Micelles structure development as a strategy to improve smart cancer therapy","volume":"10","author":"Hanafy","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.119385_bib213","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/pharmaceutics17010036","article-title":"Liposomal formulations: a recent update","volume":"17","author":"Agrawal","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119385_bib214","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12951-023-02195-5","article-title":"Ultrasound-activated prodrug-loaded liposome for efficient cancer targeting therapy without chemotherapy-induced side effects","volume":"22","author":"Jiang","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ejmech.2026.119385_bib215","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0014-5793(90)81016-H","article-title":"Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes","volume":"268","author":"Klibanov","year":"1990","journal-title":"FEBS (Fed. Eur. Biochem. Soc.) Lett."},{"key":"10.1016\/j.ejmech.2026.119385_bib216","article-title":"Liposome formulation for tumor-targeted drug delivery using radiation therapy","volume":"23","author":"Stolarz","year":"2022","journal-title":"Indian J. Manag. Sci."},{"key":"10.1016\/j.ejmech.2026.119385_bib217","first-page":"2643","article-title":"Liposomes for tumor targeted therapy: a review","volume":"24","author":"Wang","year":"2023","journal-title":"Indian J. Manag. Sci."},{"key":"10.1016\/j.ejmech.2026.119385_bib218","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120571","article-title":"Design of liposomes as drug delivery system for therapeutic applications","volume":"601","author":"Guimar\u00e3es","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2026.119385_bib219","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13550-019-0509-6","article-title":"A phase 0 study of the pharmacokinetics, biodistribution, and dosimetry of 188Re-liposome in patients with metastatic tumors","volume":"9","author":"Wang","year":"2019","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.ejmech.2026.119385_bib220","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3052175","article-title":"Preparation of drug\u2010loaded albumin nanoparticles and its application in cancer therapy","volume":"2022","author":"Meng","year":"2022","journal-title":"J. Nanomater."},{"key":"10.1016\/j.ejmech.2026.119385_bib221","doi-asserted-by":"crossref","first-page":"6945","DOI":"10.2147\/IJN.S467876","article-title":"Albumin nanoparticle-based drug delivery systems","volume":"19","author":"Qu","year":"2024","journal-title":"IJN"},{"key":"10.1016\/j.ejmech.2026.119385_bib222","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40005-024-00687-6","article-title":"Recent advances in albumin nanoparticle-based cancer therapies","volume":"55","author":"Shrestha","year":"2025","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.ejmech.2026.119385_bib223","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1021\/acs.inorgchem.4c05269","article-title":"Exploring the structure\u2013activity relationships of albumin-targeted Picoplatin-Based Platinum(IV) prodrugs","volume":"64","author":"Dijkstra","year":"2025","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib224","doi-asserted-by":"crossref","DOI":"10.1016\/j.nano.2026.102910","article-title":"Cisplatin(IV)-fatty acid prodrug-bound albumin nanoparticles: in vitro, in silico, and in vivo evaluation in breast cancer therapy","volume":"72","author":"Katari","year":"2026","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.ejmech.2026.119385_bib225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.128281","article-title":"Human serum albumin-oxaliplatin (Pt(IV)) prodrug nanoparticles with dual reduction sensitivity as effective nanomedicine for triple-negative breast cancer","volume":"256","author":"Paul","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejmech.2026.119385_bib226","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s11671-025-04411-7","article-title":"Harnessing albumin's natural tumor-targeting properties: nanoplatform strategies for triple-negative breast cancer therapy","volume":"21","author":"Sheikh","year":"2026","journal-title":"Discover Nano"},{"key":"10.1016\/j.ejmech.2026.119385_bib227","author":"Kadri"},{"key":"10.1016\/j.ejmech.2026.119385_bib228","doi-asserted-by":"crossref","DOI":"10.1093\/rb\/rbae135","article-title":"Homologous-adhering\/targeting cell membrane- and cell-mediated delivery systems: a cancer-catch-cancer strategy in cancer therapy","volume":"12","author":"Liu","year":"2025","journal-title":"Regen. Biomater."},{"key":"10.1016\/j.ejmech.2026.119385_bib229","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.3390\/nano14211757","article-title":"Blood cell membrane-coated nanomaterials as a versatile biomimetic nanoplatform for antitumor applications","volume":"14","author":"Shen","year":"2024","journal-title":"Nanomaterials"},{"key":"10.1016\/j.ejmech.2026.119385_bib230","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12951-024-02298-7","article-title":"Exosome-based delivery strategies for tumor therapy: an update on modification, loading, and clinical application","volume":"22","author":"Yang","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ejmech.2026.119385_bib231","doi-asserted-by":"crossref","first-page":"10608","DOI":"10.1039\/D4RA01026D","article-title":"Cancer cell membrane-coated nanoparticles: a promising anti-tumor bionic platform","volume":"14","author":"Guo","year":"2024","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2026.119385_bib232","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3390\/pharmaceutics16040531","article-title":"Cell membrane-coated biomimetic nanoparticles in cancer treatment","volume":"16","author":"Zhang","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119385_bib233","article-title":"Construction of bionic nanoparticles camouflaged with macrophage membranes for drug delivery in breast cancer","volume":"84","author":"Yan","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejmech.2026.119385_bib234","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2026.172706","article-title":"Ultrasound-glutathione dual-responsive bionic nanoparticles activate STING-mediated cancer immunotherapy by inducing oxidative stress storm","volume":"529","author":"Yu","year":"2026","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.ejmech.2026.119385_bib235","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/IJN.S496982","article-title":"NIR triggered bionic bilayer membrane-encapsulated nanoparticles for synergistic photodynamic, photothermal and chemotherapy of cervical cancer","volume":"20","author":"Ding","year":"2025","journal-title":"IJN"},{"key":"10.1016\/j.ejmech.2026.119385_bib236","doi-asserted-by":"crossref","first-page":"23276","DOI":"10.1021\/acsnano.5c06202","article-title":"Cancer cell membrane-coated homodimer prodrug nanoassemblies to simultaneously deliver prodrugs and immune adjuvants for combined chemo-immunotherapy","volume":"19","author":"Zhao","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejmech.2026.119385_bib237","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.3390\/pharmaceutics17101336","article-title":"Exosome-based drug delivery: a next-generation platform for cancer, infection, neurological and immunological diseases, gene therapy and regenerative medicine","volume":"17","author":"Serrano","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119385_bib238","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1039\/D4NA00501E","article-title":"A comprehensive review of challenges and advances in exosome-based drug delivery systems","volume":"6","author":"Palakurthi","year":"2024","journal-title":"Nanoscale Adv."},{"key":"10.1016\/j.ejmech.2026.119385_bib239","doi-asserted-by":"crossref","DOI":"10.1002\/smo.20240030","article-title":"Recent progress in stimuli\u2010activable metallo\u2010prodrugs for cancer therapy","volume":"2","author":"Liang","year":"2024","journal-title":"Smart Molecules"},{"key":"10.1016\/j.ejmech.2026.119385_bib240","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.biotechadv.2013.11.009","article-title":"pH-Sensitive nano-systems for drug delivery in cancer therapy","volume":"32","author":"Liu","year":"2014","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.ejmech.2026.119385_bib241","doi-asserted-by":"crossref","first-page":"6545","DOI":"10.2147\/IJN.S250549","article-title":"A pH-Sensitive prodrug nanocarrier based on diosgenin for doxorubicin delivery to efficiently inhibit tumor metastasis","volume":"15","author":"Wei","year":"2020","journal-title":"IJN"},{"key":"10.1016\/j.ejmech.2026.119385_bib242","article-title":"Platinum prodrug nanoparticles with COX\u20102 inhibition amplify pyroptosis for enhanced chemotherapy and immune activation of pancreatic cancer","volume":"36","author":"Yu","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ejmech.2026.119385_bib243","article-title":"Tumor-overexpressed enzyme responsive amphiphiles small molecular self-assembly nano-prodrug for the chemo-phototherapy against non-small-cell lung cancer","volume":"21","author":"Liu","year":"2023","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.ejmech.2026.119385_bib244","doi-asserted-by":"crossref","first-page":"8894","DOI":"10.1021\/acs.jmedchem.5c00533","article-title":"Photo-activated Ferrocene-Iridium(III) prodrug induces immunogenic cell death in melanoma stem cells","volume":"68","author":"Lie","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib245","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1021\/acsptsci.5c00442","article-title":"Photoactivatable Cisplatin-Combretastatin-BODIPY Pt(IV) prodrug for dual-action light-controlled chemotherapy","volume":"8","author":"Spector","year":"2025","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2026.119385_bib246","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1021\/acs.bioconjchem.7b00749","article-title":"Synthesis and characterization of nitric oxide-releasing Platinum(IV) prodrug and polymeric micelle triggered by light","volume":"29","author":"Pramanick","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib247","doi-asserted-by":"crossref","first-page":"21000","DOI":"10.1039\/D5SC05710H","article-title":"Ultrasound-triggered prodrug activation via sonochemically induced cleavage of a 3,5-dihydroxybenzyl carbamate scaffold","volume":"16","author":"Fu","year":"2025","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2026.119385_bib248","doi-asserted-by":"crossref","first-page":"32654","DOI":"10.1021\/acsnano.5c10301","article-title":"Ultrasound-mediated piezocatalysis triggers NO release to augment targeted immunotherapy of pancreatic cancer","volume":"19","author":"Song","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejmech.2026.119385_bib249","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1021\/acsnano.2c09948","article-title":"Ultrasound-triggered piezocatalysis for selectively controlled NO gas and chemodrug release to enhance drug penetration in pancreatic cancer","volume":"17","author":"Wang","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejmech.2026.119385_bib250","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-44683-6","article-title":"Low-frequency magnetic fields potentiate plasma-modified magneto-electric nanoparticle drug loading for anticancer activity in vitro and in vivo","volume":"13","author":"Mahdikia","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119385_bib251","article-title":"Induced electric fields inhibit breast cancer growth and metastasis by modulating the immune tumor microenvironment","author":"Charan","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.ejmech.2026.119385_bib252","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118485","article-title":"Exogenous\/endogenous stimuli-responsive antitumor prodrugs advance precision chemotherapy","volume":"132","author":"Wang","year":"2026","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib253","doi-asserted-by":"crossref","first-page":"40753","DOI":"10.1021\/acsami.4c08899","article-title":"NIR light and GSH dual-responsive upconversion nanoparticles loaded with multifunctional Platinum(IV) prodrug and RGD peptide for precise cancer therapy","volume":"16","author":"Liu","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ejmech.2026.119385_bib254","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1021\/acsnano.4c15115","article-title":"Platinum(IV)-Backboned polymer prodrug-functionalized manganese oxide nanoparticles for enhanced lung cancer chemoimmunotherapy via amplifying stimulator of interferon genes activation","volume":"19","author":"Liu","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejmech.2026.119385_bib255","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1177\/1535370220934038","article-title":"Hypoxic tumor microenvironment: implications for cancer therapy","volume":"245","author":"Roy","year":"2020","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.ejmech.2026.119385_bib256","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103327","article-title":"Tumor hypoxia: the major culprit behind cisplatin resistance in cancer patients","volume":"162","author":"Devarajan","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejmech.2026.119385_bib257","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.7150\/thno.51797","article-title":"Cisplatin-resistant NSCLC cells induced by hypoxia transmit resistance to sensitive cells through exosomal PKM2","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2026.119385_bib258","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s13402-024-00969-z","article-title":"Acidity and hypoxia of tumor microenvironment, a positive interplay in extracellular vesicle release by tumor cells","volume":"48","author":"Peppicelli","year":"2025","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.ejmech.2026.119385_bib259","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","article-title":"Role of hypoxia in cancer therapy by regulating the tumor microenvironment","volume":"18","author":"Jing","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.119385_bib260","doi-asserted-by":"crossref","first-page":"106","DOI":"10.5306\/wjco.v7.i1.106","article-title":"Role of copper transporters in platinum resistance","volume":"7","author":"Kilari","year":"2016","journal-title":"WJCO"},{"key":"10.1016\/j.ejmech.2026.119385_bib261","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1158\/1541-7786.MCR-22-0056","article-title":"Emerging roles of the Copper\u2013CTR1 axis in tumorigenesis","volume":"20","author":"Su","year":"2022","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119385_bib262","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12253-011-9449-9","article-title":"ABCC2 (MRP2, cMOAT) localized in the nuclear envelope of breast carcinoma cells correlates with poor clinical outcome","volume":"18","author":"Maciejczyk","year":"2012","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.ejmech.2026.119385_bib263","doi-asserted-by":"crossref","first-page":"7149","DOI":"10.1158\/1078-0432.CCR-06-0564","article-title":"ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome","volume":"12","author":"Surowiak","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119385_bib264","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.lungcan.2014.04.005","article-title":"Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer","volume":"85","author":"Kim","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejmech.2026.119385_bib265","first-page":"774","volume":"vol. 55","author":"Li","year":"2017"},{"key":"10.1016\/j.ejmech.2026.119385_bib266","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1479-5876-10-21","article-title":"Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC)","volume":"10","author":"Li","year":"2012","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.119385_bib267","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","article-title":"Molecular mechanisms of resistance and toxicity associated with platinating agents","volume":"33","author":"Rabik","year":"2007","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2026.119385_bib268","first-page":"867","article-title":"GSTP1 and cancer: expression, methylation, polymorphisms and signaling (Review)","volume":"56","author":"Cui","year":"2020","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2026.119385_bib269","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.canlet.2018.06.028","article-title":"The multifaceted role of glutathione S-transferases in cancer","volume":"433","author":"Chatterjee","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2026.119385_bib270","first-page":"1647","article-title":"Personalized prescription of chemotherapy based on assessment of mRNA expression of BRCA1, RRM1, ERCC1, TOP1, TOP2\u03b1, TUB\u03b23, TYMS, and GSTP1 genes in tumors compared to standard chemotherapy in the treatment of non-small-cell lung cancer","volume":"12","author":"Tsyganov","year":"2022","journal-title":"J. Phys. Math."},{"key":"10.1016\/j.ejmech.2026.119385_bib271","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s13402-021-00613-0","article-title":"DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targets","volume":"44","author":"Lozinski","year":"2021","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.ejmech.2026.119385_bib272","series-title":"Epigenetic Alterations in Oncogenesis","first-page":"3","article-title":"DNA methyltransferases, DNA damage repair, and cancer","author":"Jin","year":"2013"},{"key":"10.1016\/j.ejmech.2026.119385_bib273","article-title":"Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: a systematic review and meta-analysis based on Asian population","volume":"18","author":"Wu","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.119385_bib274","doi-asserted-by":"crossref","first-page":"544","DOI":"10.5306\/wjco.v12.i7.544","article-title":"Mechanisms of acquired resistance of BRCA1\/2-driven tumors to platinum compounds and PARP inhibitors","volume":"12","author":"Imyanitov","year":"2021","journal-title":"WJCO"},{"key":"10.1016\/j.ejmech.2026.119385_bib275","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173718","article-title":"Mismatch repair protein MLH1 suppresses replicative stress in BRCA2-deficient breast tumors","volume":"134","author":"Sengodan","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2026.119385_bib276","first-page":"1","article-title":"Multi-pathway therapeutics in colorectal cancer: targeting EMT, CSCs, and non-apoptotic cell death for drug resistance reversal","author":"Hu","year":"2025","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejmech.2026.119385_bib277","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.3390\/nu16213741","article-title":"Potential strategies for overcoming drug resistance pathways using propolis and its polyphenolic\/flavonoid compounds in combination with chemotherapy and radiotherapy","volume":"16","author":"Or\u0161oli\u0107","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.ejmech.2026.119385_bib278","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.bbrc.2005.03.190","article-title":"p53 mutation heterogeneity in cancer","volume":"331","author":"Soussi","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2026.119385_bib279","first-page":"4002","article-title":"Association of the epithelial\u2013mesenchymal transition (EMT) with cisplatin resistance","volume":"21","author":"Ashrafizadeh","year":"2020","journal-title":"Indian J. Manag. Sci."},{"key":"10.1016\/j.ejmech.2026.119385_bib280","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1186\/s12967-022-03776-y","article-title":"Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial\u2013mesenchymal transition interlinked with reprogrammed metabolism","volume":"20","author":"Leung","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.119385_bib281","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e41483","article-title":"Molecular mechanisms of mTOR-mediated cisplatin response in tumor cells","volume":"11","author":"Maharati","year":"2025","journal-title":"Heliyon"},{"key":"10.1016\/j.ejmech.2026.119385_bib282","article-title":"Platinum-resistant ovarian cancer: from mechanisms to treatment strategies","volume":"13","author":"Li","year":"2026","journal-title":"Genes Dis."},{"key":"10.1016\/j.ejmech.2026.119385_bib283","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12885-016-2182-8","article-title":"Platinum (IV)-fatty acid conjugates overcome inherently and acquired cisplatin resistant cancer cell lines: an in-vitro study","volume":"16","author":"Ratzon","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejmech.2026.119385_bib284","doi-asserted-by":"crossref","first-page":"13455","DOI":"10.1021\/acs.jmedchem.5c00086","article-title":"Platinum(IV) prodrug with a docosahexaenoic acid ligand preferentially accumulates in drug-resistant cells and triggers ferroptosis to overcome drug resistance","volume":"68","author":"Zhou","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib285","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.bmcl.2011.01.092","article-title":"Overcoming biochemical pharmacologic mechanisms of platinum resistance with a texaphyrin\u2013platinum conjugate","volume":"21","author":"Arambula","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119385_bib286","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1021\/acs.molpharmaceut.8b00070","article-title":"A carrier-free nanostructure based on Platinum(IV) prodrug enhances cellular uptake and cytotoxicity","volume":"15","author":"Tan","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2026.119385_bib287","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s42004-022-00661-z","article-title":"A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance","volume":"5","author":"Fronik","year":"2022","journal-title":"Commun. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib288","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jinorgbio.2019.01.014","article-title":"A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer","volume":"193","author":"Chen","year":"2019","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2026.119385_bib289","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/bjc.2014.386","article-title":"Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines","volume":"111","author":"Sawers","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119385_bib290","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3390\/ph18040563","article-title":"Histone deacetylase inhibitors promote the anticancer activity of cisplatin: mechanisms and potential","volume":"18","author":"Zhou","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.119385_bib291","first-page":"9248","article-title":"Role of nucleotide excision repair in cisplatin resistance","volume":"21","author":"Duan","year":"2020","journal-title":"Indian J. Manag. Sci."},{"key":"10.1016\/j.ejmech.2026.119385_bib292","first-page":"1414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Indian J. Manag. Sci."},{"key":"10.1016\/j.ejmech.2026.119385_bib293","doi-asserted-by":"crossref","first-page":"15564","DOI":"10.1002\/anie.201608936","article-title":"A Platinum(IV) anticancer prodrug targeting nucleotide excision repair to overcome cisplatin resistance","volume":"55","author":"Wang","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119385_bib294","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00432-015-2026-y","article-title":"Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents","volume":"142","author":"Xue","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119385_bib295","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.589906","article-title":"A new platinum-based prodrug candidate for chemotherapy and its synergistic effect with hadrontherapy: novel strategy to treat glioblastoma","volume":"15","author":"Ferrari","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ejmech.2026.119385_bib296","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1506206","article-title":"Platinum(IV) anticancer therapies and cathepsin B: innovative strategies for overcoming resistance in glioblastoma cells","volume":"13","author":"Casali","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2026.119385_bib297","first-page":"3049","article-title":"Different patterns of platinum resistance in ovarian cancer cells with homologous recombination proficient and deficient background","volume":"25","author":"Chiappa","year":"2024","journal-title":"Indian J. Manag. Sci."},{"key":"10.1016\/j.ejmech.2026.119385_bib298","series-title":"Mitochondrial Medicine","first-page":"409","article-title":"Assessing impact of platinum complexes on mitochondrial functions","author":"Jin","year":"2021"},{"key":"10.1016\/j.ejmech.2026.119385_bib299","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.biomaterials.2013.09.036","article-title":"Enhanced cytotoxicity to cancer cells by mitochondria-targeting MWCNTs containing platinum(IV) prodrug of cisplatin","volume":"35","author":"Yoong","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejmech.2026.119385_bib300","doi-asserted-by":"crossref","first-page":"22063","DOI":"10.1039\/D5RA02064F","article-title":"Synthesis and anticancer activity of Pt(iv) prodrugs containing 3-bromopyruvic acid as an axial ligand","volume":"15","author":"Zhou","year":"2025","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2026.119385_bib301","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.chembiol.2013.08.010","article-title":"Targeting mitochondrial DNA with a platinum-based anticancer agent","volume":"20","author":"Wisnovsky","year":"2013","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119385_bib302","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12943-021-01440-5","article-title":"Exosomes in the hypoxic TME: from release, uptake and biofunctions to clinical applications","volume":"21","author":"He","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.119385_bib303","doi-asserted-by":"crossref","first-page":"1","DOI":"10.61424\/ijmhr.v4i1.666","article-title":"Overcoming tumor hypoxia and acidic microenvironment to convert photodynamic therapy into a systemic antitumor immune response","volume":"4","author":"Abdukarimova","year":"2026","journal-title":"International Journal of Medical and Health Research"},{"key":"10.1016\/j.ejmech.2026.119385_bib304","doi-asserted-by":"crossref","first-page":"18556","DOI":"10.1002\/anie.202005362","article-title":"CAIXplatins: highly potent Platinum(IV) prodrugs selective against carbonic anhydrase IX for the treatment of hypoxic tumors","volume":"59","author":"Cao","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119385_bib305","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1039\/D4MD00876F","article-title":"Nitroaromatic-based triazene prodrugs to target the hypoxic microenvironment in glioblastoma","volume":"16","author":"Braga","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119385_bib306","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1158\/1535-7163.MCT-21-0406","article-title":"Selectively targeting tumor hypoxia with the hypoxia-activated prodrug CP-506","volume":"20","author":"Van Der Wiel","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.119385_bib307","first-page":"43","article-title":"Comparison of the effects of the oral anticancer platinum(IV) complexes oxoplatin and metabolite cis-diammine-tetrachlorido-platinum(IV) on global gene expression of NCI-H526 cells","author":"Hamilton","year":"2011","journal-title":"JEP 2011"},{"key":"10.1016\/j.ejmech.2026.119385_bib308","doi-asserted-by":"crossref","first-page":"11360","DOI":"10.1039\/D2SC03375E","article-title":"A platinum\u2013ruthenium hybrid prodrug with multi-enzymatic activities for chemo-catalytic therapy of hypoxic tumors","volume":"13","author":"Yang","year":"2022","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2026.119385_bib309","article-title":"Combination of IDO inhibitors and platinum(IV) prodrugs reverses low immune responses to enhance cancer chemotherapy and immunotherapy for osteosarcoma","volume":"20","author":"Xiang","year":"2023","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.ejmech.2026.119385_bib310","doi-asserted-by":"crossref","first-page":"14854","DOI":"10.1021\/jacs.5b10182","article-title":"A Pt(IV) pro-drug preferentially targets Indoleamine-2,3-dioxygenase, providing enhanced ovarian cancer immuno-chemotherapy","volume":"137","author":"Awuah","year":"2015","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.119385_bib311","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1039\/D5QI00433K","article-title":"Albumin-targeted oxaliplatin(iv) prodrugs bearing STING agonists","volume":"12","author":"Dijkstra","year":"2025","journal-title":"Inorg. Chem. Front."},{"key":"10.1016\/j.ejmech.2026.119385_bib312","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jpha.2023.11.002","article-title":"Antibody-platinum (IV) prodrugs conjugates for targeted treatment of cutaneous squamous cell carcinoma","volume":"14","author":"Yin","year":"2024","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.ejmech.2026.119385_bib313","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12943-025-02410-x","article-title":"PEGylated PLGA nanoparticles: unlocking advanced strategies for cancer therapy","volume":"24","author":"Kesharwani","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.119385_bib314","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3390\/life14060672","article-title":"Targeted liposomal drug delivery: overview of the current applications and challenges","volume":"14","author":"Gatto","year":"2024","journal-title":"Life"},{"key":"10.1016\/j.ejmech.2026.119385_bib315","first-page":"185","article-title":"Pt(IV) prodrug initiated microparticles from microfluidics for tumor chemo-, photothermal and photodynamic combination therapy","volume":"24","author":"Zhang","year":"2023","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.ejmech.2026.119385_bib316","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.msec.2018.10.092","article-title":"Delivery of platinum (II) drugs with bulky ligands in trans-geometry for overcoming cisplatin drug resistance","volume":"96","author":"Yang","year":"2019","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.ejmech.2026.119385_bib317","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1021\/ja0432618","article-title":"Rational design of Platinum(IV) compounds to overcome Glutathione-S-Transferase mediated drug resistance","volume":"127","author":"Ang","year":"2005","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.119385_bib318","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119385_bib319","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1158\/0008-5472.CAN-12-2217","article-title":"Intratumor heterogeneity: evolution through space and time","volume":"72","author":"Swanton","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119385_bib320","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/j.semnuclmed.2015.09.002","article-title":"Development of companion diagnostics","volume":"46","author":"Mankoff","year":"2016","journal-title":"Semin. Nucl. Med."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426008305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426008305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:56:21Z","timestamp":1793966181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426008305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":320,"alternative-id":["S0223523426008305"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119385","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multifunctional platinum(IV) prodrugs: Targeted delivery, stimuli-responsive release, and precision oncology","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119385","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119385"}}